Cargando…
Evaluation of the Developmental Toxicity of Vedolizumab, an α(4)β(7) Receptor Antagonist, in Rabbit and Nonhuman Primate
Vedolizumab, a humanized monoclonal antibody approved for the treatment of adults with moderately to severely active ulcerative colitis or Crohn disease, targets α(4)β(7) integrin and selectively blocks gut-specific lymphocyte trafficking. The potential effects of vedolizumab on development were ass...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749749/ https://www.ncbi.nlm.nih.gov/pubmed/31364424 http://dx.doi.org/10.1177/1091581819864105 |